• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Gynecol Cancer . Clinical impact of SARS-CoV-2 infection among patients with vulvar cancer: the Gemelli Vul.Can multidisciplinary team

tetano

Editor, Senior Moderator
Int J Gynecol Cancer


. 2021 Dec 13;ijgc-2021-003026.
doi: 10.1136/ijgc-2021-003026. Online ahead of print.
Clinical impact of SARS-CoV-2 infection among patients with vulvar cancer: the Gemelli Vul.Can multidisciplinary team


Alex Federico[SUP] 1 [/SUP], Simona Maria Fragomeni[SUP] 2 [/SUP], Luca Tagliaferri[SUP] 3 [/SUP], Linda Stella Guajardo Rios[SUP] 4 [/SUP], Valentina Lancellotta[SUP] 3 [/SUP], Stefano Gentileschi[SUP] 5 6 [/SUP], Giacomo Corrado[SUP] 1 [/SUP], Benedetta Gui[SUP] 7 [/SUP], Giuseppe Colloca[SUP] 3 [/SUP], Vittoria Rufini[SUP] 8 9 [/SUP], Anna Fagotti[SUP] 1 10 [/SUP], Giovanni Scambia[SUP] 1 10 [/SUP], Giorgia Garganese[SUP] 10 11 [/SUP]



Affiliations

Abstract

Background: 'Severe acute respiratory syndrome coronavirus-2' (SARS-CoV-2) infection has dramatically affected the management of patients with cancer, who are most vulnerable to the consequences of the infection. Patients with vulvar cancer are frequently elderly and affected by multiple co-morbidities, thus representing a particularly frail population.
Objective: To assess the clinical impact of the SARS-CoV-2 infection among patients scheduled for treatment for active vulvar cancer.
Methods: Data on patients with vulvar tumors referred to Fondazione Policlinico Universitario Agostino Gemelli IRCCS between February 2020 and July 2021 were retrospectively analyzed. Patients with a positive reverse transcription polymerase chain reaction in nasopharyngeal swab were considered as positive for SARS-Cov-2.
Results: One hundred and ninety-one patients with vulvar cancer were evaluated and scheduled for treatment. The median age was 72 years (range 35-94). Seven (3.7%) patients were diagnosed with SARS-Cov-2 infection: three (42.9%) had their treatment delayed, with no apparent consequences, two (28.6%) had their treatment delayed and later abandoned because of clinical worsening due to oncologic disease progression, and two (28.6%) contracted the infection in the post-operative period and died due to respiratory complications.
Conclusions: In most cases the infection had major clinical implications, being associated with significant delays in oncologic treatments and extremely high mortality when contracted in the post-operative period.

Keywords: COVID-19; vulvar and vaginal cancer; vulvar neoplasms.
 
Back
Top Bottom